India M&A Trends: Rational Valuations, Foreign Firms Shed Products
This article was originally published in PharmAsia News
Executive Summary
Rational valuations and the potential divestment of older portfolios by foreign firms were some of the key mergers and acquisitions (M&A) trends highlighted by industry experts at a recent congress in India.
You may also be interested in...
M&A Trends: Private Equity And 'Aspirational' Execs Pair Up In India
Private equity firms partnering with senior management professionals bitten by the entrepreneurial bug to buy pharmaceutical businesses in India were some of the emerging trends highlighted by experts at a recent CPhI congress in Mumbai. Scrip covers the key conference highlights on the "maturing" Indian M&A market, including how foreign firms are shedding their older portfolios to reallocate resources to newer products.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet